BioCryst Pharmaceuticals vs ACADIA Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

BioCryst Pharmaceuticals Inc (BCRX)

Q3 202629 Jun – 23 Sep 2026

▲3

BioCryst Swings to Profit, Raises Guidance, Expands ORLADEYO

Raised 2026 revenue guidance and first profit BioCryst lifted full-year revenue guidance to $690–715 million and cut cost guidance, after Q2 revenue jumped 34% to $218 million and the company posted its first profit. More sales and lower costs mean more cash, which supports a higher stock price.
This is the core new financial event that directly improves earnings and investor confidence.
ORLADEYO pediatric expansion in US and Japan Japan approved ORLADEYO for children aged 2–12, the first oral preventive there, and US pellet shipments began with 47 quick prescriptions. A wider label means more patients and future sales, pushing the stock up.
New regulatory approval and real pediatric uptake expand the market for the main revenue drug.
Takeover speculation on first profitable year Analysts see Takeda as a likely buyer because its HAE drug Takhzyro is threatened by BioCryst's navenibart, with AstraZeneca also named. No talks are confirmed, but the buzz can lift the shares as investors bet on a deal.
New speculation about a buyout adds a potential premium to the stock price.
Closing internal discovery, shifting to external deals BioCryst is closing its Birmingham research site and ending internal discovery to cut costs and buy rare-disease assets instead. This saves money now but reduces long-term self-generated innovation, and the company still has negative equity and $822 million in debt.
This strategic shift and the debt load are the main counterweights to the positive profit and guidance news.

August 202629 Jun – 23 Sep 2026

▲3

BioCryst Swings to Profit, Raises Guidance, Expands ORLADEYO

Raised 2026 revenue guidance and first profit BioCryst lifted full-year revenue guidance to $690–715 million and cut cost guidance, after Q2 revenue jumped 34% to $218 million and the company posted its first profit. More sales and lower costs mean more cash, which supports a higher stock price.
This is the core new financial event that directly improves earnings and investor confidence.
ORLADEYO pediatric expansion in US and Japan Japan approved ORLADEYO for children aged 2–12, the first oral preventive there, and US pellet shipments began with 47 quick prescriptions. A wider label means more patients and future sales, pushing the stock up.
New regulatory approval and real pediatric uptake expand the market for the main revenue drug.
Takeover speculation on first profitable year Analysts see Takeda as a likely buyer because its HAE drug Takhzyro is threatened by BioCryst's navenibart, with AstraZeneca also named. No talks are confirmed, but the buzz can lift the shares as investors bet on a deal.
New speculation about a buyout adds a potential premium to the stock price.
Closing internal discovery, shifting to external deals BioCryst is closing its Birmingham research site and ending internal discovery to cut costs and buy rare-disease assets instead. This saves money now but reduces long-term self-generated innovation, and the company still has negative equity and $822 million in debt.
This strategic shift and the debt load are the main counterweights to the positive profit and guidance news.

Latest29 Jun – 23 Sep 2026

▲3

BioCryst Swings to Profit, Raises Guidance, Expands ORLADEYO

Raised 2026 revenue guidance and first profit BioCryst lifted full-year revenue guidance to $690–715 million and cut cost guidance, after Q2 revenue jumped 34% to $218 million and the company posted its first profit. More sales and lower costs mean more cash, which supports a higher stock price.
This is the core new financial event that directly improves earnings and investor confidence.
ORLADEYO pediatric expansion in US and Japan Japan approved ORLADEYO for children aged 2–12, the first oral preventive there, and US pellet shipments began with 47 quick prescriptions. A wider label means more patients and future sales, pushing the stock up.
New regulatory approval and real pediatric uptake expand the market for the main revenue drug.
Takeover speculation on first profitable year Analysts see Takeda as a likely buyer because its HAE drug Takhzyro is threatened by BioCryst's navenibart, with AstraZeneca also named. No talks are confirmed, but the buzz can lift the shares as investors bet on a deal.
New speculation about a buyout adds a potential premium to the stock price.
Closing internal discovery, shifting to external deals BioCryst is closing its Birmingham research site and ending internal discovery to cut costs and buy rare-disease assets instead. This saves money now but reduces long-term self-generated innovation, and the company still has negative equity and $822 million in debt.
This strategic shift and the debt load are the main counterweights to the positive profit and guidance news.

ACADIA Pharmaceuticals Inc (ACAD)

Q3 202620 Jul – 25 Sep 2026

▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.
This is the period's dominant new event and the main reason ACAD moved.
Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.
It is the main new positive force supporting ACAD's price this period.
Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.
Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.
Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.
Explains the regulatory and demand backdrop behind the remlifanserin story.

August 202620 Jul – 25 Sep 2026

▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.
This is the period's dominant new event and the main reason ACAD moved.
Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.
It is the main new positive force supporting ACAD's price this period.
Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.
Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.
Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.
Explains the regulatory and demand backdrop behind the remlifanserin story.

Latest20 Jul – 25 Sep 2026

▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.
This is the period's dominant new event and the main reason ACAD moved.
Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.
It is the main new positive force supporting ACAD's price this period.
Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.
Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.
Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.
Explains the regulatory and demand backdrop behind the remlifanserin story.